KCT0004141已完成未知
Clinical studies comparing the pharmacokinetic properties and safety of oral administration of KD5001 with those of amlodipine / valsartan and rosuvastatin in healthy adult volunteers
Kyung Dong Pharmaceutical0 个研究点目标入组 48 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 48
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional Study
入排标准
- 年龄范围
- 19?(Year) 至 o Limit（—）
- 性别
- All
入选标准
- •1) ???? ?? ?? ??? ? 19? ?? ??? ??
- •2) Those who have a body mass index (BMI) of 18.5 kg / m2 to 27.0 kg / m2 at screening
- •3) Patients with no congenital or chronic disease and no medically symptomatic findings
- •4) Those who have been determined to be eligible as a result of clinical tests and electrocardiogram tests, such as serum tests, hematology tests, blood chemistry tests, and urine tests, which were performed by the doctor in charge within 4 weeks prior to administration of the clinical trial drug
- •5) After fully hearing and understanding the details of this clinical trial, you agree to voluntarily decide to participate and to comply with the Notice
排除标准
- •1) Persons who have a history of hypersensitivity reactions or other clinically significant hypersensitivity to other drugs or additives in the main components or components of clinical trial medicines
- •2) Persons with a history of drug absorption, distribution, metabolism, and excretion
- •3) Patients with hereditary angioedema or with a history of angioedema when treated with ACE inhibitors or angiotensin II receptor antagonists
- •4) Patients with genetic problems such as galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption
- •5) If there is a history or family history of genetic myopathy
- •6) ?? HMG-CoA ???? ??? ?? ?????? ?? ?? ??? ??? ?? ??
- •7) In patients with vital signs, the left systolic blood pressure = 140 mmHg or <115 mmHg, the left ventricular diastolic blood pressure = 90 mmHg or <70 mmHg
- •8) ??? ??? ?? ?? AST, ALT, total bilirubin? ?? ?? ???? 1.5?? ???? ?
- •9) Creatinine clearance <80 mL / min (creatinine clearance is calculated by Cockcroft-Gault formula using serum creatinine)
- •10) Patients who have gastrointestinal diseases (Crohn's disease, active peptic ulcer, etc.) that may affect the absorption of clinical trial medications or gastrointestinal surgery (except for simple cecal surgery or hernia surgery)
- •11) Any person who has suffered a major injury within 4 weeks prior to the first dose, or who has undergone surgical procedures and who has suspected acute illness (severe infectious disease, severe trauma, severe diarrhea, vomiting, etc.)
- •12) (Cigarettes> 10 cfu / day) who are unable to abstain during the clinical trial from 3 days prior to the clinical trial, or those who are unable to continue drinking during the trial (21units / week, 1unit = 10g = 12.5mL of pure alcohol)
- •13) From the screening date until 30 days after the last clinical trial drug administration, appropriate double-pregnancy or medically acceptable contraceptive methods (including intrauterine devices with proven pregnancy failure rates, physical contraceptive methods and spermicide) Use, vasectomy, tubal resection / ligation, hysterectomy, etc.)
- •14) Women who are pregnant or who may be pregnant and breastfeeding
- •15) Any person taking any OTC medicines or herbal medicines within 2 weeks of the first day of medication or who has taken any OTC medication within 1 week will be subject to the judgment of the examiner that the medication will affect the test or the safety of the subject When it is judged to be influential
- •16) Those who have participated in other clinical studies within 6 months before the first administration day
- •17) Those who donated whole blood within 2 months before the first administration day, or those who donated blood within 1 month
- •18) Those who have had abnormal diets that can affect the absorption, distribution, metabolism and excretion of the drug (eg, take 1 mg or more of the grapefruit juice daily within 7 days prior to administration of the clinical trial drug)
- •19) Serum test (HBsAg, HCV Ab, HIV Ag / Ab, VDRL) Result positive
- •20) Those who are judged to be ineligible for participation in clinical trials at the discretion of the examiner and the examiner (doctor in charge)
研究者
相似试验
招募中
不适用
Clinical Trials to Compare the Pharmacokinetic Profiles of Sarpogrelate hydrochloride 300mg SR Tablet and ANPLAG® IR After Multiple Oral Administration to Healthy Male SubjectsKCT0000156Kunwha Pharmaceutical18
招募中
不适用
Clinical Trials to Compare the Pharmacokinetic Profiles of Sarpogrelate hydrochloride 300mg SR Tablet and ANPLAG® IR After Oral Administration to Healthy Male SubjectsKCT0000202Kunwha Pharmaceutical18
招募中
不适用
A study to compare the pharmacokinetics profile of DWCZP tablet 100mg and Clozaril® tablet 100mg.Mental and behavioral disordersKCT0000531Dong Hwa Pharm28
进行中（未招募）
不适用
A trial to compare the pharmacokinetics and pharmacodynamics of insulin lispro administered s.c. into lipohypertrophic or normal abdominal adipose tissue in subjects with diabetes mellitus type 1MedDRA version: 17.0Level: LLTClassification code 10045228Term: Type I diabetes mellitusSystem Organ Class: 100000004861Diabetes mellitusEUCTR2014-003144-12-DEProfil Institut für Stoffwechselforschung GmbH
进行中（未招募）
1 期
A research study of how fast-acting insulin aspart works in the body of children, young people and grown-ups with type 1 diabetesDiabetes Mellitus, Type 1MedDRA version: 20.0Level: LLTClassification code 10045228Term: Type I diabetes mellitusSystem Organ Class: 100000004861EUCTR2017-002014-31-DEovo Nordisk A/S43